Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Shortening Buruli Ulcer Treatment with Combination Therapy Targeting the Respiratory Chain and Exploiting Mycobacterium ulcerans Gene Decay.

Converse PJ, Almeida DV, Tyagi S, Xu J, Nuermberger EL.

Antimicrob Agents Chemother. 2019 Jun 24;63(7). pii: e00426-19. doi: 10.1128/AAC.00426-19. Print 2019 Jul.

PMID:
31036687
2.

Advancing the Therapeutic Potential of Indoleamides for Tuberculosis.

Lun S, Tasneen R, Chaira T, Stec J, Onajole OK, Yang TJ, Cooper CB, Mdluli K, Converse PJ, Nuermberger EL, Raj VS, Kozikowski A, Bishai WR.

Antimicrob Agents Chemother. 2019 Jun 24;63(7). pii: e00343-19. doi: 10.1128/AAC.00343-19. Print 2019 Jul.

3.

Understanding the Significance of Biochemistry in the Storage, Handling, Purification, and Sampling of Amphiphilic Mycolactone.

Kubicek-Sutherland JZ, Vu DM, Anderson AS, Sanchez TC, Converse PJ, Martí-Arbona R, Nuermberger EL, Swanson BI, Mukundan H.

Toxins (Basel). 2019 Apr 4;11(4). pii: E202. doi: 10.3390/toxins11040202.

4.

Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis.

Xu J, Li SY, Almeida DV, Tasneen R, Barnes-Boyle K, Converse PJ, Upton AM, Mdluli K, Fotouhi N, Nuermberger EL.

Antimicrob Agents Chemother. 2019 Apr 25;63(5). pii: e00021-19. doi: 10.1128/AAC.00021-19. Print 2019 May.

5.

Oxazolidinones Can Replace Clarithromycin in Combination with Rifampin in a Mouse Model of Buruli Ulcer.

Almeida DV, Omansen TF, Li SY, Lee J, Grosset JH, Converse PJ, Nuermberger EL.

Antimicrob Agents Chemother. 2019 Feb 26;63(3). pii: e02171-18. doi: 10.1128/AAC.02171-18. Print 2019 Mar.

PMID:
30559131
6.

High-Dose Rifamycins Enable Shorter Oral Treatment in a Murine Model of Mycobacterium ulcerans Disease.

Omansen TF, Almeida D, Converse PJ, Li SY, Lee J, Stienstra Y, van der Werf T, Grosset JH, Nuermberger EL.

Antimicrob Agents Chemother. 2019 Jan 29;63(2). pii: e01478-18. doi: 10.1128/AAC.01478-18. Print 2019 Feb.

7.

Shorter-course treatment for Mycobacterium ulcerans disease with high-dose rifamycins and clofazimine in a mouse model of Buruli ulcer.

Converse PJ, Almeida DV, Tasneen R, Saini V, Tyagi S, Ammerman NC, Li SY, Anders NM, Rudek MA, Grosset JH, Nuermberger EL.

PLoS Negl Trop Dis. 2018 Aug 13;12(8):e0006728. doi: 10.1371/journal.pntd.0006728. eCollection 2018 Aug.

8.

A multi-antigenic MVA vaccine increases efficacy of combination chemotherapy against Mycobacterium tuberculosis.

Leung-Theung-Long S, Coupet CA, Gouanvic M, Schmitt D, Ray A, Hoffmann C, Schultz H, Tyagi S, Soni H, Converse PJ, Arias L, Kleinpeter P, Sansas B, Mdluli K, Vilaplana C, Cardona PJ, Nuermberger E, Marchand JB, Silvestre N, Inchauspé G.

PLoS One. 2018 May 2;13(5):e0196815. doi: 10.1371/journal.pone.0196815. eCollection 2018.

9.

Immunodeficiency and Intermittent Dosing Promote Acquired Rifamycin Monoresistance in Murine Tuberculosis.

Park SW, Tasneen R, Converse PJ, Nuermberger EL.

Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e01502-17. doi: 10.1128/AAC.01502-17. Print 2017 Nov.

10.

Bactericidal and Sterilizing Activity of a Novel Regimen with Bedaquiline, Pretomanid, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis.

Li SY, Tasneen R, Tyagi S, Soni H, Converse PJ, Mdluli K, Nuermberger EL.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e00913-17. doi: 10.1128/AAC.00913-17. Print 2017 Sep.

11.

New Paradigm for Translational Modeling to Predict Long-term Tuberculosis Treatment Response.

Bartelink IH, Zhang N, Keizer RJ, Strydom N, Converse PJ, Dooley KE, Nuermberger EL, Savic RM.

Clin Transl Sci. 2017 Sep;10(5):366-379. doi: 10.1111/cts.12472. Epub 2017 May 31.

12.

Mouse model of pulmonary cavitary tuberculosis and expression of matrix metalloproteinase-9.

Ordonez AA, Tasneen R, Pokkali S, Xu Z, Converse PJ, Klunk MH, Mollura DJ, Nuermberger EL, Jain SK.

Dis Model Mech. 2016 Jul 1;9(7):779-88. doi: 10.1242/dmm.025643. Epub 2016 May 26.

13.

Contribution of Oxazolidinones to the Efficacy of Novel Regimens Containing Bedaquiline and Pretomanid in a Mouse Model of Tuberculosis.

Tasneen R, Betoudji F, Tyagi S, Li SY, Williams K, Converse PJ, Dartois V, Yang T, Mendel CM, Mdluli KE, Nuermberger EL.

Antimicrob Agents Chemother. 2015 Oct 26;60(1):270-7. doi: 10.1128/AAC.01691-15. Print 2016 Jan.

14.

Efficacy of Rifampin Plus Clofazimine in a Murine Model of Mycobacterium ulcerans Disease.

Converse PJ, Tyagi S, Xing Y, Li SY, Kishi Y, Adamson J, Nuermberger EL, Grosset JH.

PLoS Negl Trop Dis. 2015 Jun 4;9(6):e0003823. doi: 10.1371/journal.pntd.0003823. eCollection 2015.

15.

Evaluation of moxifloxacin-containing regimens in pathologically distinct murine tuberculosis models.

Li SY, Irwin SM, Converse PJ, Mdluli KE, Lenaerts AJ, Nuermberger EL.

Antimicrob Agents Chemother. 2015 Jul;59(7):4026-30. doi: 10.1128/AAC.00105-15. Epub 2015 Apr 27.

16.

Characterization of mouse models of Mycobacterium avium complex infection and evaluation of drug combinations.

Andréjak C, Almeida DV, Tyagi S, Converse PJ, Ammerman NC, Grosset JH.

Antimicrob Agents Chemother. 2015 Apr;59(4):2129-35. doi: 10.1128/AAC.04841-14. Epub 2015 Jan 26.

17.

Clofazimine shortens the duration of the first-line treatment regimen for experimental chemotherapy of tuberculosis.

Tyagi S, Ammerman NC, Li SY, Adamson J, Converse PJ, Swanson RV, Almeida DV, Grosset JH.

Proc Natl Acad Sci U S A. 2015 Jan 20;112(3):869-74. doi: 10.1073/pnas.1416951112. Epub 2015 Jan 5.

18.

Accelerated detection of mycolactone production and response to antibiotic treatment in a mouse model of Mycobacterium ulcerans disease.

Converse PJ, Xing Y, Kim KH, Tyagi S, Li SY, Almeida DV, Nuermberger EL, Grosset JH, Kishi Y.

PLoS Negl Trop Dis. 2014 Jan 2;8(1):e2618. doi: 10.1371/journal.pntd.0002618. eCollection 2014.

19.

Rapid, serial, non-invasive assessment of drug efficacy in mice with autoluminescent Mycobacterium ulcerans infection.

Zhang T, Li SY, Converse PJ, Grosset JH, Nuermberger EL.

PLoS Negl Trop Dis. 2013 Dec 19;7(12):e2598. doi: 10.1371/journal.pntd.0002598. eCollection 2013.

20.

Assessment of clofazimine activity in a second-line regimen for tuberculosis in mice.

Grosset JH, Tyagi S, Almeida DV, Converse PJ, Li SY, Ammerman NC, Bishai WR, Enarson D, Trébucq A.

Am J Respir Crit Care Med. 2013 Sep 1;188(5):608-12. doi: 10.1164/rccm.201304-0753OC.

21.

Microbiological, histological, immunological, and toxin response to antibiotic treatment in the mouse model of Mycobacterium ulcerans disease.

Sarfo FS, Converse PJ, Almeida DV, Zhang J, Robinson C, Wansbrough-Jones M, Grosset JH.

PLoS Negl Trop Dis. 2013;7(3):e2101. doi: 10.1371/journal.pntd.0002101. Epub 2013 Mar 14.

22.

Bactericidal activity does not predict sterilizing activity: the case of rifapentine in the murine model of Mycobacterium ulcerans disease.

Almeida DV, Converse PJ, Li SY, Tyagi S, Nuermberger EL, Grosset JH.

PLoS Negl Trop Dis. 2013;7(2):e2085. doi: 10.1371/journal.pntd.0002085. Epub 2013 Feb 28.

23.

Improving existing tools for Mycobacterium xenopi treatment: assessment of drug combinations and characterization of mouse models of infection and chemotherapy.

Andréjak C, Almeida DV, Tyagi S, Converse PJ, Ammerman NC, Grosset JH.

J Antimicrob Chemother. 2013 Mar;68(3):659-65. doi: 10.1093/jac/dks421. Epub 2012 Nov 5.

24.

Modeling early bactericidal activity in murine tuberculosis provides insights into the activity of isoniazid and pyrazinamide.

Grosset J, Almeida D, Converse PJ, Tyagi S, Li SY, Ammerman NC, Pym AS, Wallengren K, Hafner R, Lalloo U, Swindells S, Bishai WR.

Proc Natl Acad Sci U S A. 2012 Sep 11;109(37):15001-5. doi: 10.1073/pnas.1203636109. Epub 2012 Aug 27.

25.

Treating Mycobacterium ulcerans disease (Buruli ulcer): from surgery to antibiotics, is the pill mightier than the knife?

Converse PJ, Nuermberger EL, Almeida DV, Grosset JH.

Future Microbiol. 2011 Oct;6(10):1185-98. doi: 10.2217/fmb.11.101. Review.

26.

BCG-mediated protection against Mycobacterium ulcerans infection in the mouse.

Converse PJ, Almeida DV, Nuermberger EL, Grosset JH.

PLoS Negl Trop Dis. 2011 Mar 15;5(3):e985. doi: 10.1371/journal.pntd.0000985.

27.

Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice.

Zhang M, Li SY, Rosenthal IM, Almeida DV, Ahmad Z, Converse PJ, Peloquin CA, Nuermberger EL, Grosset JH.

Am J Respir Crit Care Med. 2011 May 1;183(9):1254-61. doi: 10.1164/rccm.201012-1949OC. Epub 2011 Feb 17.

28.

Activities of rifampin, Rifapentine and clarithromycin alone and in combination against mycobacterium ulcerans disease in mice.

Almeida D, Converse PJ, Ahmad Z, Dooley KE, Nuermberger EL, Grosset JH.

PLoS Negl Trop Dis. 2011 Jan 4;5(1):e933. doi: 10.1371/journal.pntd.0000933.

29.

Using bioluminescence to monitor treatment response in real time in mice with Mycobacterium ulcerans infection.

Zhang T, Li SY, Converse PJ, Almeida DV, Grosset JH, Nuermberger EL.

Antimicrob Agents Chemother. 2011 Jan;55(1):56-61. doi: 10.1128/AAC.01260-10. Epub 2010 Nov 15.

30.

The impact of mouse passaging of Mycobacterium tuberculosis strains prior to virulence testing in the mouse and guinea pig aerosol models.

Converse PJ, Eisenach KD, Theus SA, Nuermberger EL, Tyagi S, Ly LH, Geiman DE, Guo H, Nolan ST, Akar NC, Klinkenberg LG, Gupta R, Lun S, Karakousis PC, Lamichhane G, McMurray DN, Grosset JH, Bishai WR.

PLoS One. 2010 Apr 21;5(4):e10289. doi: 10.1371/journal.pone.0010289.

31.

Studies of a ring-cleaving dioxygenase illuminate the role of cholesterol metabolism in the pathogenesis of Mycobacterium tuberculosis.

Yam KC, D'Angelo I, Kalscheuer R, Zhu H, Wang JX, Snieckus V, Ly LH, Converse PJ, Jacobs WR Jr, Strynadka N, Eltis LD.

PLoS Pathog. 2009 Mar;5(3):e1000344. doi: 10.1371/journal.ppat.1000344. Epub 2009 Mar 20.

32.

Role of the dosR-dosS two-component regulatory system in Mycobacterium tuberculosis virulence in three animal models.

Converse PJ, Karakousis PC, Klinkenberg LG, Kesavan AK, Ly LH, Allen SS, Grosset JH, Jain SK, Lamichhane G, Manabe YC, McMurray DN, Nuermberger EL, Bishai WR.

Infect Immun. 2009 Mar;77(3):1230-7. doi: 10.1128/IAI.01117-08. Epub 2008 Dec 22.

33.
34.

Selective killing of nonreplicating mycobacteria.

Bryk R, Gold B, Venugopal A, Singh J, Samy R, Pupek K, Cao H, Popescu C, Gurney M, Hotha S, Cherian J, Rhee K, Ly L, Converse PJ, Ehrt S, Vandal O, Jiang X, Schneider J, Lin G, Nathan C.

Cell Host Microbe. 2008 Mar 13;3(3):137-45. doi: 10.1016/j.chom.2008.02.003.

35.

Accelerated detection of Mycobacterium tuberculosis genes essential for bacterial survival in guinea pigs, compared with mice.

Jain SK, Hernandez-Abanto SM, Cheng QJ, Singh P, Ly LH, Klinkenberg LG, Morrison NE, Converse PJ, Nuermberger E, Grosset J, McMurray DN, Karakousis PC, Lamichhane G, Bishai WR.

J Infect Dis. 2007 Jun 1;195(11):1634-42. Epub 2007 Apr 23.

PMID:
17471433
36.

Agreement between Mantoux skin testing and QuantiFERON-TB assay using dual mycobacterial antigens in current and former injection drug users.

Shah SS, McGowan JP, Klein RS, Converse PJ, Blum S, Gourevitch MN.

Med Sci Monit. 2006 Apr;12(4):MT11-6. Epub 2006 Mar 28.

PMID:
16572060
37.
38.

Attenuation of late-stage disease in mice infected by the Mycobacterium tuberculosis mutant lacking the SigF alternate sigma factor and identification of SigF-dependent genes by microarray analysis.

Geiman DE, Kaushal D, Ko C, Tyagi S, Manabe YC, Schroeder BG, Fleischmann RD, Morrison NE, Converse PJ, Chen P, Bishai WR.

Infect Immun. 2004 Mar;72(3):1733-45.

39.
40.

Characterization of the role of the divalent metal ion-dependent transcriptional repressor MntR in the virulence of Staphylococcus aureus.

Ando M, Manabe YC, Converse PJ, Miyazaki E, Harrison R, Murphy JR, Bishai WR.

Infect Immun. 2003 May;71(5):2584-90.

41.

Comparison between a whole blood interferon-gamma release assay and tuberculin skin testing for the detection of tuberculosis infection among patients at risk for tuberculosis exposure.

Kimura M, Converse PJ, Astemborski J, Rothel JS, Vlahov D, Comstock GW, Graham NM, Chaisson RE, Bishai WR.

J Infect Dis. 1999 May;179(5):1297-300.

PMID:
10191241
42.

Pulmonary bovine-type tuberculosis in rabbits: bacillary virulence, inhaled dose effects, tuberculin sensitivity, and Mycobacterium vaccae immunotherapy.

Converse PJ, Dannenberg AM Jr, Shigenaga T, McMurray DN, Phalen SW, Stanford JL, Rook GA, Koru-Sengul T, Abbey H, Estep JE, Pitt ML.

Clin Diagn Lab Immunol. 1998 Nov;5(6):871-81.

43.

Distress, symptom distress, and immune function in women with suspected breast cancer.

DeKeyser FG, Wainstock JM, Rose L, Converse PJ, Dooley W.

Oncol Nurs Forum. 1998 Sep;25(8):1415-22.

PMID:
9766295
44.

Nonspecific and immune-specific up-regulation of cytokines in rabbit dermal tuberculous (BCG) lesions.

Sugisaki K, Dannenberg AM Jr, Abe Y, Tsuruta J, Su WJ, Said W, Feng L, Yoshimura T, Converse PJ, Mounts P.

J Leukoc Biol. 1998 Apr;63(4):440-50.

PMID:
9544573
45.
46.

Cavitary tuberculosis produced in rabbits by aerosolized virulent tubercle bacilli.

Converse PJ, Dannenberg AM Jr, Estep JE, Sugisaki K, Abe Y, Schofield BH, Pitt ML.

Infect Immun. 1996 Nov;64(11):4776-87.

47.
48.
49.
50.

Supplemental Content

Loading ...
Support Center